FDA approves Teva allergy drug

JERUSALEM — The Food and Drug Administration has approved a drug made by Teva for treating allergies, the company said Monday.

Teva announced the approval of Qnasl (beclomethasone dipropionate) for seasonal and year-round nasal allergies in patients ages 12 years and older. The company said the drug, a "dry" nasal aerosol, would become available next month.

"There are some patients with allergic rhinitis who report dissatisfaction with the currently available therapies," Dallas Asthma and Allergy Center allergist Gary Gross said in a statement on behalf of Teva. "The approval of Qnasl offers these patients a safe and effective treatment option with a new dry mode of delivery."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.